This antibody was produced from antiserum of rabbits immunized with a recombinant SARS-CoV-2 S1 RBD protein. The IgG fraction was purified by Protein A affinity chromatography.
Recommended Applications
ELISA (recommended work dilution = 1:160,000)
Reconstitution
Product is supplied as a powder obtained from lyophilization of purified antibody in 1X PBS, aliquot using ddH2O. Reconstitute the antibody with sterile water to a final concentration of 1 mg/ml.
It's been reported that 2019-nCoV (COVID-19) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Specificity
This antibody was selected for its ability to bind to the virus SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) from the disease COVID-19.
Storage
Store at 4°C if intended for use within one month, otherwise, store at -20°C to -80°C. The lyophilized antibody is stable for at least 18 months after the date of receipt when stored at -20°C to -80°C. After reconstitution, it can be aliquoted and stored frozen at -20°C to -80°C in a manual defrost freezer for at least 6 months without detectable loss of activity. Upon reconstitution, the antibody can also be stored for 1 month at 4°C. Please avoid freeze-thaw cycles, as this will lower the activity of the antibody.
Expiration
12 months from the date of shipment when stored properly.
McCafferty S, Haque AA, Vandierendonck A, Weidensee B, Plovyt M, StuchlÃková M, François N, Valembois S, Heyndrickx L, Michiels J, Ariën KK. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. Molecular Therapy. 2022 Sep 7;30(9):2968-83.
Azad T, Singaravelu R, Taha Z, Jamieson TR, Boulton S, Crupi MJ, Martin NT, Fekete EE, Poutou J, Ghahremani M, Pelin A. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. Molecular Therapy. 2021 Jun 2;29(6):1984-2000.